DK0652752T3 - Vanddispergerbare tabletter - Google Patents

Vanddispergerbare tabletter

Info

Publication number
DK0652752T3
DK0652752T3 DK93917926T DK93917926T DK0652752T3 DK 0652752 T3 DK0652752 T3 DK 0652752T3 DK 93917926 T DK93917926 T DK 93917926T DK 93917926 T DK93917926 T DK 93917926T DK 0652752 T3 DK0652752 T3 DK 0652752T3
Authority
DK
Denmark
Prior art keywords
pct
date
sec
disintegrating agent
water dispersible
Prior art date
Application number
DK93917926T
Other languages
Danish (da)
English (en)
Inventor
Suryakant Dahyabhai Patel
Michael John Desmond Gamlen
Krystyna Elzbieta Fielden
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0652752T3 publication Critical patent/DK0652752T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Paints Or Removers (AREA)
DK93917926T 1992-07-27 1993-07-27 Vanddispergerbare tabletter DK0652752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929215908A GB9215908D0 (en) 1992-07-27 1992-07-27 Water dispersible tablets
PCT/GB1993/001586 WO1994002147A1 (en) 1992-07-27 1993-07-27 Water-dispersible tablets

Publications (1)

Publication Number Publication Date
DK0652752T3 true DK0652752T3 (da) 2000-03-20

Family

ID=10719356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93917926T DK0652752T3 (da) 1992-07-27 1993-07-27 Vanddispergerbare tabletter

Country Status (14)

Country Link
US (1) US5698221A (es)
EP (1) EP0652752B1 (es)
JP (1) JPH07509463A (es)
AT (1) ATE184486T1 (es)
AU (1) AU4717193A (es)
DE (1) DE69326470T2 (es)
DK (1) DK0652752T3 (es)
ES (1) ES2137267T3 (es)
GB (1) GB9215908D0 (es)
GR (1) GR3031679T3 (es)
IL (1) IL106492A0 (es)
MX (1) MX9304502A (es)
WO (1) WO1994002147A1 (es)
ZA (1) ZA935381B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009934A (es) * 1999-03-29 2002-06-21 American Home Prod Sistema de recubrimiento.
BR0013366A (pt) * 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
EP1700591A4 (en) 2003-12-01 2011-08-03 Takeda Pharmaceutical PROCESS FOR TREATING SOLID PHARMACEUTICAL PREPARATION PRIOR TO PRINTING AND SOLID PHARMACEUTICAL PREPARATION SUBJECT TO PROCESSING BEFORE PRINTING
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
CN101291655A (zh) * 2005-10-19 2008-10-22 诺瓦提斯公司 包含地拉罗司(deferasirox)的分散片
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
KR20120012823A (ko) * 2009-04-29 2012-02-10 렉산 파마슈티컬스, 인코포레이티드 신경보호 및 퇴행성 신경 질환 치료용 클라블라네이트 제제

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB777516A (en) * 1955-04-14 1957-06-26 Griffiths Hughes Ltd E Improvements in or relating to the production of tablets by pressure
GB837451A (en) * 1956-02-20 1960-06-15 Arner Co Inc Sustained release therapeutic composition and process of preparing same
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
US3427379A (en) * 1966-01-13 1969-02-11 Hoffmann La Roche Dextromethorphan and benzyl alcohol hard candy lozenges free from opaqueness and/or tiny entrapped air bubbles
NL6814269A (es) * 1967-10-13 1969-04-15
DE2016622A1 (en) * 1970-04-08 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Anthelmintic benzimidazole deriv
FR2096292A5 (es) * 1970-06-15 1972-02-11 Sumitomo Chemical Co
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2183546B1 (es) * 1972-05-10 1975-06-20 Servier Lab
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
US4209513A (en) * 1974-02-14 1980-06-24 Burroughs Wellcome Co. Tablet formulation
DE2416903A1 (de) * 1974-04-06 1975-10-09 Bayer Ag Verwendung von schmelzverspruehtem kugelfoermigem phenacetingranulat zur herstellung von tabletten im direkttablettierverfahren
JPS5154918A (en) * 1974-10-08 1976-05-14 Nippon Kayaku Kk Jozaino seizoho
US4086335A (en) * 1975-10-29 1978-04-25 Bruscato Frank N Pharmaceutical tablets containing chitin as a disintegrant
DE2552967A1 (de) * 1975-11-26 1977-06-08 Bayer Ag Fungizide mittel
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
DE2849494A1 (de) * 1978-11-15 1980-05-29 Voss Gunter M Verfahren zur herstellung von arzneimittel-formlingen
ZA803250B (en) * 1979-06-01 1982-01-27 Wellcome Found Substituded aromatic compounds
US4251518A (en) * 1979-07-03 1981-02-17 Ralston Purina Company Method of preparing readily disintegrable pharmaceutical compositions
US4304773A (en) * 1980-06-26 1981-12-08 E. R. Squibb & Sons, Inc. Novel bendroflumethiazide formulations and method
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
HU189534B (en) * 1981-09-09 1986-07-28 Chinoin Rt.,Hu Process for producing new tablets containing cyclodextrin polymer as desintegrator
DE3142826A1 (de) * 1981-10-29 1983-05-11 Rütgerswerke AG, 6000 Frankfurt Verfahren zur herstellung einer hochreaktiven pechfraktion und deren verwendung
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4661521A (en) * 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
DE3505433A1 (de) * 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen Direkttablettierhilfsmittel
US4631305A (en) * 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
EP0199855A1 (en) * 1985-05-02 1986-11-05 Gist-Brocades N.V. Tablets comprising tromethoprim and a sulfonamide
US4832956A (en) * 1985-09-25 1989-05-23 Gerhard Gergely Disintegrating tablet and process for its preparation
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
JPH01501934A (ja) * 1986-04-01 1989-07-06 ジ・アップジョン・カンパニー メチルプレドニソロン／カルボキシメチルスターチナトリウム錠剤組成物
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
DE3635864A1 (de) * 1986-06-26 1988-05-05 Gerhard Gergely Verfahren zum herstellen eines brausegranulates, danach hergestelltes brausegranulat sowie dessen verwendung
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
KR960001372B1 (ko) * 1986-09-24 1996-01-26 예일 유니버시티 레트로비루스로 감염된 환자의 치료에 사용되는 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 항생물질
US4771077A (en) * 1986-10-21 1988-09-13 American Home Products Corporation (Del.) Spray dried acetaminophen
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
ATE73328T1 (de) * 1987-05-08 1992-03-15 Smith Kline French Lab Pharmazeutische zusammensetzungen.
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
ATE68346T1 (de) * 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
DE3806633A1 (de) * 1987-09-01 1989-03-09 Bayer Ag Antivirales mittel
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
DE68916983T2 (de) * 1988-02-25 1995-01-19 Yamanouchi Europ Bv Verfahren zur Herstellung eines pharmazeutischen Granulats.
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
IT1226549B (it) * 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
YU183988A (en) * 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
US4965072A (en) * 1988-11-03 1990-10-23 Miles Inc. Granulating composition and method
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
DE59006174D1 (de) * 1989-04-07 1994-07-28 Ciba Geigy Ag Pestizide Wirkstoffkonzentrate und ihre Herstellung.
US4970078A (en) * 1989-05-25 1990-11-13 Aqualon Company Crosslinked carboxymethyguar tablet disintegrant
DK0490920T3 (da) * 1989-09-07 1994-04-25 Gerhard Gergely Mavesyrebindende farmaceutisk præparat
US5037658A (en) * 1989-09-14 1991-08-06 Hoechst-Roussel Pharmaceuticals, Inc. Direct dry compressible acetaminophen composition
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
GB9025372D0 (en) * 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms

Also Published As

Publication number Publication date
IL106492A0 (en) 1993-11-15
EP0652752A1 (en) 1995-05-17
WO1994002147A1 (en) 1994-02-03
GB9215908D0 (en) 1992-09-09
US5698221A (en) 1997-12-16
DE69326470D1 (de) 1999-10-21
GR3031679T3 (en) 2000-02-29
MX9304502A (es) 1994-06-30
EP0652752B1 (en) 1999-09-15
ZA935381B (en) 1995-01-26
DE69326470T2 (de) 2000-01-13
AU4717193A (en) 1994-02-14
ES2137267T3 (es) 1999-12-16
ATE184486T1 (de) 1999-10-15
JPH07509463A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
DK0652752T3 (da) Vanddispergerbare tabletter
FR2700117B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
NO952229L (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
ZA200005217B (en) α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders.
SE9500209D0 (sv) Treatment of cerebral ischemia and cerebral damage with neuroprotective agent
DE69223965D1 (de) Anticonvulsives aminosäurederivat
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
BG104686A (en) Glycine transport inhibitors
AR028705A1 (es) Bis-arilsulfonas
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
DK0646009T3 (da) Anvendelse af guanosin til fremstilling af lægemidler beregnet til behandling af cerebrale funktionsdefekter
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
DK0691846T3 (da) Imidazoquinoxalinoner til behandling af sygdomme i centralnervesystemet
DK1196176T5 (da) Anvendelse af beta-naphthoquinonderivater til fremstilling af lægemidler, der har en hæmmende virkning på hjernens afgivelse af glutamat
TNSN99199A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc A LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION